[Edaily Reporter KYUNG GYEYOUNG ] Sulwhasoo, the global luxury beauty brand operated by AMOREPACIFIC CORPORATION(090430), relaunched its exfoliating “White Ginseng Mask” on the 1st after a six-year hiatus.
The White Ginseng Mask is a product that gently removes dead skin cells accumulated on the skin’s surface to reveal a clear and smooth complexion, incorporating Sulwhasoo’s research on white ginseng and its expertise in exfoliation. It is a wash-off mask.
With this relaunch, Sulwhasoo focused on enhancing the Baek Sam Pack’s user experience and perceptible efficacy. The Baek Sam powder removes unnecessary dead skin cells from the skin’s surface and smooths the skin texture, while the Jaeumdan formula ensures the skin remains comfortable even after use. Additionally, it provides a subtle warming sensation upon application, offering an experience akin to a steam massage.
Recently, interest in “Skin Prep” products—which enhance the effectiveness of skincare and makeup—has been growing in the cosmetics market. Sulwhasoo anticipates that the White Ginseng Mask will attract attention for its ability to improve the absorption and adhesion of skincare products and ensure makeup applies more evenly.
A Sulwhasoo brand representative stated, “Through this relaunch, we will provide a premium ‘Skin Prep’ experience that not only exfoliates but also refines skin texture and radiance.”
The White Ginseng Pack is available starting today at Sulwhasoo stores nationwide, flagship stores, the official Sulwhasoo online store, and major online platforms.
ABLE C&C(078520)is establishing a subsidiary in the Netherlands to serve as the control tower for its European operations. Following the establishment of its UK subsidiary, the company is setting up a…
On the afternoon of the 18th, at the Vuori pop-up store in Seongsu-dong, Seongdong-gu, Seoul, a different scene unfolded as I passed through the first and second floors—where clothes were displayed—an…
AprilBio Co.,Ltd.(397030)has decided to explore other indications for “APB-A1” (Lu AG22515), a technology it licensed to Lundbeck, after the compound failed to demonstrate the expected clinical effica…